RxDoctor Payments Data

Marise Kelly, MD

Family Medicine · Houston, TXNPI 1124056304

Payments from drug & device makers

$1,278in general payments, 2019–2025

Across 65 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$390
  • Merck$134
  • Abbott$107
  • Amgen$101
  • Pfizer$85
  • Novartis$84
  • plus $377 from 10 others

What the payments were for

  • Food & beverage$1,278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,278 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,250
Medicare patients
42
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin204$205,660
TrulicityDulaglutide62$62,902
OzempicSemaglutide23$29,577
FarxigaDapagliflozin Propanediol19$24,920
JanuviaSitagliptin Phosphate21$23,253
TradjentaLinagliptin21$14,235
EliquisApixaban12$11,023
VascepaIcosapent Ethyl17$9,680
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,833
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,386
SymbicortBudesonide/Formoterol Fumarate16$5,537
Omega-3 Acid Ethyl Esters33$4,510
Levemir FlexpenInsulin Detemir16$3,522
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,055
Fluticasone Propionate HfaFluticasone Propionate14$2,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$53$62,90262 claims
AstraZenecaFarxiga, Symbicort$390$30,45735 claims
Novo NordiskOzempic$63$29,57723 claims
MerckJanuvia$134$23,25321 claims
PfizerEliquis$85$11,02312 claims
GSKTrelegy Ellipta$72$8,83314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →